current standards in bcg-unresponsive carcinoma in-situ and papillary nmibc
Published 2 years ago • 389 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
2:08
core1 trial: cg0070 plus pembrolizumab for bcg-unresponsive carcinoma-in-situ bladder cancer
-
1:55
durvalumab monotherapy for patients with bcg-unresponsive carcinoma-in-situ bladder cancer
-
0:27
cretostimogene plus pembrolizumab for bcg-unresponsive nmibc with cis #bladdercancer #cancer #news
-
3:04
high-risk, bcg-unresponsive nmibc beyond rc: intravesical and systemic therapies
-
1:02
results of n-803, an il-15rαfc superagonist, with bcg in bcg-unresponsive cis and nmibc
-
2:01
keynote-057 cohort b: pembrolizumab for bcg-unresponsive, high-risk nmibc
-
11:45
emerging treatments for bcg unresponsive non-muscle invasive bladder cancer
-
10:35
management of bcg unresponsive cystectomy ineligible bladder cancer patients pembrolizumab
-
1:56
real-world evaluation of nadofaragene firadenovec in bcg-unresponsive nmibc
-
1:54
innovations in treatment options for patients with bcg-unresponsive urothelial carcinoma
-
21:04
bcg unresponsive non-muscle invasive bladder cancer
-
3:17
n-803-bcg combination shows promising results in bcg-unresponsive nmibc
-
1:08:04
understanding the evolving treatment landscape in bladder cancer
-
1:12
scott tagawa, md, on the study investigating nadofaragene firadenovec in bcg unresponsive nmibc
-
19:31
second line bladder cancer therapies when first line treatments fail
-
29:46
introduction to adstiladrin | gene therapy for bcg unresponsive nmibc
-
53:45
oligometastatic renal cancer and bcg-unresponsive non-muscle-invasive bladder cancer
-
19:31
adaptive immune resistance to intravesical bcg in nmibc: bcg-unresponsive clinical trials
-
0:36
key unmet needs in bladder cancer